AMT Medical’s $25M Boost to Innovate Heart Surgery Techniques

AMT Medical B.V., a pioneering medtech company from the Netherlands, has successfully secured $25 million in Series B funding, spearheaded by Bender Analytical Holding B.V. This significant financial injection will accelerate the development of their ELANA® Heart Bypass System, a groundbreaking minimally invasive technology aimed at revolutionising coronary artery bypass surgery by enabling bypasses without the need for traditional open-heart procedures. 

This funding is timely as the cardiovascular surgery market seeks viable alternatives to conventional methods that often involve sternotomy and prolonged recovery. AMT’s innovative ELANA® Heart Bypass System leverages a proprietary clip and excimer laser for sutureless vessel connection, permitting precise graft integration while minimising complications. The procedure is performed on a beating heart, reducing stroke risk and potentially cutting costs by over 50% in robotic settings. The new capital influx will support AMT’s plans to gain CE marking by 2026, further facilitating human trials in Europe and clinical evaluations in the U.S. This innovation holds promise not just for patient outcomes but also in economic terms, given its potential to shorten hospital stays and accelerate surgeon training.

With this fresh round of funding, AMT Medical is well-positioned to usher in a new era of cardiac surgery. The advancement by AMT has the potential to not only enhance patient care but also transform operational dynamics within surgical wards, offering a glimpse into a future where heart surgeries are safer and more efficient.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Holly Haynes today!